NCT03249402View on ClinicalTrials.gov

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

November 24, 2017

Study Completion Date

November 24, 2017

Conditions
Healthy
Interventions
DRUG

Ethinyl Estradiol + Levonorgestrel

Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.

DRUG

JNJ-42847922

Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.

Trial Locations (1)

2060

SGS Life Science Services, Antwerp

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY

NCT03249402 - A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants | Biotech Hunter | Biotech Hunter